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ABSTRACT   21 
Metallo-β-lactamases (MBLs) are the major group of carbapenemases produced by 22 
bacterial pathogens. The design of MBL inhibitors has been limited, among other issues, by the 23 
incomplete knowledge about how these enzymes modulate substrate recognition. While most 24 
MBLs are broad-spectrum enzymes, B2 MBLs are exclusive carbapenemases. This narrower 25 
substrate profile has been attributed to a sequence insertion present in B2 enzymes that limits the 26 
accessibility to the active site. In this work, we evaluate the role of sequence insertions naturally 27 
occurring in the B2 enzyme Sfh-I and in the broad-spectrum B1 enzyme SPM-1. We engineered 28 
a chimeric protein in which the sequence insertion of SPM-1 was replaced by the one present in 29 
Sfh-I. The chimeric variant is a selective cephalosporinase, revealing that the substrate profile of 30 
MBLs can be further tuned depending on the protein context. These results also show that the 31 
stable scaffold of MBLs allows a modular engineering much richer than the one observed in 32 
nature. 33 
 34 
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The worldwide spread of resistance to antibiotics has raised a global concern, particularly 37 
regarding carbapenem-resistant Enterobacteriaceae. The largest group of carbapenemases is 38 
comprised by metallo-β-lactamases (MBLs) (1), which are Zn(II)-dependent β-lactamases able to 39 
hydrolyze most β-lactam drugs (2, 3). MBL genes, which are common in environmental bacteria, 40 
have disseminated into MDR Gram-negative pathogens helped by mobile genetic elements. 41 
Outbreaks of multirresistant Enterobacteriaceae, Pseudomonas aeruginosa or Acinetobacter 42 
baumanii producing NDMs, VIMs, IMPs or SPM-1 MBLs are ubiquitous worldwide (4). Most 43 
worrisome, no clinical inhibitors against these enzymes are available (3).  44 
MBLs share a general protein fold and an active site where one or two Zn(II) ions are 45 
required for substrate binding and catalysis (2, 5). Within this common fold, the surroundings of 46 
the active site are highly variable and impact on the substrate and inhibition profiles (6), and in 47 
the host adaptability of these enzymes (7). These variable regions dictate the clinical evolution of 48 
MBLs as they include most of the mutational hotspots (8–11). Despite their relevance, the role of  49 
individual residues or loop-structures around the active site is incompletely understood, limiting 50 
our knowledge on how MBLs modulate their substrate profile, and ultimately hindering the 51 
design of a common inhibitor (6, 12). Understanding the molecular features that shape the 52 
substrate profile of MBLs appears also as a challenge to comprehend the evolution of these 53 
enzymes (7).  54 
The structural diversity of MBLs has led to a classification into three subclasses: B1, B2 and 55 
B3, each one with a unique arrangement of conserved metal ligands, loops and a set of second-56 
shell residues around the active site, that define the substrate specificity (2, 6). B1 MBLs (the 57 
most clinically relevant MBLs) contain a solvent-accessible active site located on a shallow 58 
groove between two flexible loops (L3 and L10) and bind two Zn(II) ions (13). Their active sites 59 





















can accommodate different types of β-lactam antibiotics (penicillins, carbapenems and 60 
cephalosporins), thus being broad-spectrum enzymes. In a similar way, B3 bimetallic active sites 61 
are solvent-accessible and are broad-spectrum, despite bearing a different loop architecture (2, 62 
6). B2 subclass MBLs, instead, are exclusive carbapenemases and only bind one Zn(II) in their 63 
active form. These enzymes harbor a truncated L3 loop and a sequence insertion in the active site 64 
(between helix α3 and β-strand β7) that introduces a “kink” generating a hydrophobic wall on the 65 
active site surface. This architecture is thought to determine the narrow substrate profile of B2 66 
enzymes (2, 13).  67 
 P. aeruginosa SPM-1 is unique among B1 enzymes in that it possesses a loop arrangement 68 
reminiscent of B2 enzymes, i.e., a shortened L3 loop and a sequence insertion between helix α3 69 
and β-strand β7 (14). Indeed, SPM-1 has been considered as a hybrid enzyme between B1 and 70 
B2 subclasses, despite its broad substrate spectrum and metal ligands that are shared with B1 71 
enzymes (15). However, the sequence insertion of SPM-1 differs in length and residue identity 72 
compared to B2 enzymes (24 residues in SPM-1 vs. 17 in B2 enzymes), suggesting different 73 
evolutionary origins (14). Here we used SPM-1 as a template for protein engineering in which 74 
we grafted the sequence insertion from the typical B2 enzyme Sfh-I aimed to restrict the 75 
substrate spectrum. The resulting chimeric protein (SPM-1/Sfh-I) showed indeed a narrower 76 
substrate spectrum, revealing that sequence insertion in this region affects substrate recognition 77 
in MBLs. It also reveals alternative evolutionary pathways still unexplored in nature that may 78 
benefit from the stable scaffold of MBLs to accumulate insertions, deletions and mutations 79 
giving rise to novel resistance phenotypes.  80 
 81 
RESULTS AND DISCUSSION 82 
Design of a chimeric protein  83 





















The chimeric SPM-1/Sfh-I protein was designed based on a structural alignment of SPM-1 84 
and Sfh-I (PDB codes 2FHX and 3SD9, respectively) (14, 16) (Figure 1A). A segment of 31 85 
residues, containing the native 24 aminoacids insertion, was removed from SPM-1 and replaced 86 
by the corresponding sequence from Sfh-I, substituting the entire region in which the three-87 
dimensional arrangements of both enzymes differ. Point mutations D226F and Y223N, in L10 88 
loop, and L119T, in L7 loop, were incorporated in SPM-1 to mimic the native interactions of the 89 
sequence insertion in Sfh-I (Figure 1B, 1C). 90 
 91 
Resistance profile and stability of the SPM-1/Sfh-I chimera in P. aeruginosa and E. coli 92 
We examined the ability of the mutant gene to express a stable and active protein in two 93 
different model hosts of MBL producers, P. aeruginosa (the natural host of SPM-1) and 94 
Escherichia coli. For this purpose, we used a P. aeruginosa PAO1 strain to produce both wild 95 
type SPM-1 and the chimeric SPM-1/Sfh-I variant. Proteins were produced fused to a C-terminal 96 
strep-tag sequence for immunoblotting detection, which does not affect the resistance profile of 97 
MBLs (17), and with the native peptide leader of SPM-1 for periplasmic localization. We 98 
measured minimal inhibitory concentration (MIC) values of different β-lactam antibiotics 99 
towards strains expressing these proteins. The SPM-1/Sfh-I chimera, unlike wild type SPM-1, 100 
was not able to confer resistance against β-lactam antibiotics in P. aeruginosa. MIC values of 101 
imipenem, piperacillin and ceftazidime were comparable to those of the control strain containing 102 
an empty vector. Similar results were obtained in Escherichia coli, revealing that inability of the 103 
chimera to confer resistance is not host-specific. 104 
We then evaluated the stability in vivo of SPM-1/Sfh-I compared to wild type SPM-1 in 105 
different cell compartments. Periplasmic and spheroplast fractions of P. aeruginosa PAO1 and E. 106 
coli DH5α expressing wild type or the chimeric protein were analyzed by Western-blot using anti 107 





















Strep-tag antibodies. As shown in Figure 2, both wild-type SPM-1 and the chimera were 108 
produced to similar levels in cells, but SPM-1/Sfh-I did not accumulate in the periplasmic 109 
fraction of these bacteria, the site of action of MBLs. These results indicate that the inability to 110 
confer resistance is due to the lack of accumulation of the chimeric protein in the periplasm, 111 
likely due to stability issues that are not host-dependent. 112 
 113 
Biochemical characterization of SPM-1 and SPM-1/Sfh-I 114 
We then characterized biochemically the chimeric protein, to assess its activity and stability 115 
in vitro. Over-expression of the chimera resulted in formation of inclusion bodies indicating that 116 
the insertion introduced in the chimeric protein is destabilizing. Similar results were obtained 117 
were obtained when trying to optimize induction conditions. Thus, we attempted recovering the 118 
protein from inclusion bodies in denaturing conditions, followed by refolding in the presence of 119 
Zn(II) by flash dilution (see Material and Methods for details). The same protocol was used with 120 
wild type SPM-1 to obtain comparable results. The procedure was successful, allowing to obtain 121 
up to 5 mg per liter of culture of folded and active protein, evaluated by nitrocefin hydrolysis.  122 
Circular dichroism (CD) in the far UV revealed the presence of secondary structure in both 123 
purified proteins (Fig. 3A). The metal content of both SPM-1/Sfh-I and wild type SPM-1 was 124 
variable among different purifications, ranging from 0.6 to 2 Zn(II) equivalents per protein, 125 
yielding an average of 1.4 Zn(II) equivalents per protein. Since B1 MBLs are prone to oxidation 126 
of the Cys221 ligand (14, 18) we measured the level of oxidation in the SPM-1/SfhI by reaction 127 
of the denatured chimera with Ellman’s reagent DTNB. This revealed that 30 % ± 5 of Cys221 is 128 
oxidized showing that failure to bind two Zn(II) equivalents stems from oxidation of this residue 129 
and not from a hybrid behavior between B1 and B2 enzymes. Altogether these results indicate 130 
that SPM-1/Sfh-I has the potential to bind two Zn(II) ions, as expected for the ligand set of a B1 131 





















lactamase. The irreversible thermal denaturation of SPM-1/Sfh-I vs. the wild type protein was 132 
determined by thermal shift assays. SPM-1 displayed a very high thermal stability (Tm = 72 °C), 133 
while the melting temperature for the chimeric protein was 51 °C. Despite this value is higher 134 
than the normal growth temperature of bacterial cells, it reveals a large destabilization in the 135 
chimera, which accounts for its scarce accumulation in the bacterial periplasm. This ultimately 136 
leads to the lack of resistance observed.  137 
 138 
In vitro β-lactamase activity 139 
The β-Lactamase activity of purified SPM-1/Sfh-I and wild type SPM-1 was determined 140 
against a wide range of β-lactam antibiotics (Table 2 and Supplementary Fig. 1). Surprisingly, in 141 
SPM-1/Sfh-I we observed substrate inhibition with cephalosporins at substrate concentrations 142 
above 100 µM, suggesting the formation of dead-end enzyme-substrate complexes 143 
(Supplementary Fig. 1). Catalytic efficiencies estimated from linear regression of the curves at 144 
[S]→0, however, revealed similar values to those measured for wild type SPM-1. In contrast, the 145 
chimeric protein displayed a large drop in the catalytic efficiencies (kcat/KM) against imipenem 146 
and penicillins (ranging between 2-3 orders of magnitude) compared to the wild type enzyme. 147 
This effect is due to a reduction in kcat values for both types of substrates, and an increase in KM 148 
only for penicillins. This suggests that the insertion of the Sfh-I sequence does not disturb 149 
binding of some substrates to the active site (as observed for B2 enzymes (19–22)), but that 150 
instead, affects their hydrolysis. Overall, SPM-1/Sfh-1 resembles B2 lactamases in that both are 151 
narrow spectrum enzymes, but while the latter are exclusive carbapenemases, the hybrid SPM-152 
1/Sfh-I shows a clear preference for cephalosporins. Finally, the similarity in catalytic 153 
efficiencies for cephalosporins in SPM-1/Sfh-I compared to SPM-1 suggests that neither binding 154 
nor hydrolysis of these substrates involve the α3 region of MBLs.  155 






















Molecular dynamics simulations 157 
The reduced stability of the SPM-1/Sfh-I chimera, together with the low yields of purified 158 
enzyme, limited the possibility of obtaining crystals and prevented us from using X-ray 159 
crystallography. We therefore decided to build a chimeric protein in-silico by homology 160 
modeling based on the reported structures of wild type SPM-1 and Sfh-I. This model was then 161 
subjected to 100 ns of Molecular Dynamics (MD) simulations using the AMBER14 package (23) 162 
at 300 K in the NVT ensemble, to observe the time evolution of its conformation. Parallel runs 163 
on wild type SPM-1 and Sfh-I were performed to specifically assess the role of the sequence 164 
insertion in the dynamics in different scaffolds. Previous work showed that the native sequence 165 
insertion of SPM-1 can adopt two conformations in equilibrium (24):  one “open” (SPM-1
open
) in 166 
which residues arrange as an extension of the α3 helix and an additional α4 helix, both exposed 167 
and oriented towards the solvent (14), and one “closed” similar to B2 enzymes (SPM-1
closed
) 168 
(Figure 4) (24, 25). The crystal structures of both forms were used as starting geometries for 169 
separate MD runs, both for the wild type SPM-1 and the chimeric protein. Figure 4A shows 170 
representative snapshots of the MD simulations of the enzymes subject of this study. All proteins 171 
maintained their general conformation during the simulations, as seen in the temporal evolution 172 
of root means square deviation (Supplementary Figure 2A). 173 
In order to monitor the conformation of the sequence insertion during the simulations, we 174 
analyzed the temporal evolution of the distance between the Zn(II) ions and the tip of the 175 
insertion (Supplementary Figure 2B). When simulations were started from the SPM-1
open
 176 
structure, the sequence insertion remained in the open conformation. Likewise, simulations 177 
starting either from SPM-1
closed
 or Sfh-I showed a closed conformation invariable over time. On 178 
the contrary, in the case of SPM-1/Sfh-I chimera, the sequence insertion fluctuated between an 179 























) and a closed (SPM-1/Sfh-I
closed
) conformation, similar to SPM-1
open
 and 180 
SPM-1
closed
 (or Sfh-I), respectively. This was evidenced as a periodic variation in the distance 181 
between Zn(II) ions and the tip of the insertion. These results show that the sequence insertion in 182 
the chimera gained dynamics. MD simulations allowed us to simulate different conformations to 183 
later study the accessibility of the substrate by Brownian Dynamics simulation (BD) simulations. 184 
BD simulations are a powerful tool for studying the motion of molecules in solution and 185 
have been widely applied to study of the encounter of an enzyme and its ligand (26). In an 186 
attempt to account for the impact of the insertion in the restricted activity profile of the chimera, 187 
we calculated the relative probability of association of a substrate (benzylpenicillin) by BD 188 
simulations, following the Zn2…N (β-lactam ring) distance as reaction criteria. We analyzed  189 
2,000,000 BD trajectories to estimate the association probability. Both SPM-1
close
 and SPM-190 
1/Sfh-I
close
 show an almost null association probability. Instead, both open forms are able to bind 191 
benzylpenicillin, but the association probability for SPM-1
open
 is 4-fold larger compared to that 192 
of SPM-1/Sfh-I
open
 (Figure 4B). Given that BD simulations consider two features, the position 193 
and the electrostatic potential of the insertion, the lower probability of association observed in 194 
SPM-1/Sfh-I
open
 may be due to the different nature of the residues present in the insertion. This 195 
result indicates that the insertion excludes the substrates to be hydrolyzed, in agreement with the 196 
reduced catalytic efficiency observed for penicillins as substrates of SPM-1/SfhI. Due to the 197 
dynamic nature of this insertion, the chimeric protein is able to hydrolyze substrates when this 198 
enzyme explores the open form conformation.  199 
 200 
DISCUSSION 201 
The continuous molecular evolution of MBLs that might render them more stable or 202 
efficient for β-lactame-hydrolysis remains a constant challenge. Because MBLs hydrolyze the 203 





















most clinical important antibiotics, understanding the determinants of their substrate profile is a 204 
major concern. It has been suggested that different protein loops, that are not necessarily part of 205 
the active site, might play a role in substrate binding, such as the mobile flap of the B1 enzymes 206 
(27). In this work, we studied the role of the sequence insertion between helix α3 and β-strand β7 207 
on the substrate selectivity of MBLs. To this end, we constructed a chimeric protein based on a 208 
B1 scaffold (SPM-1), substituting its natural insertion sequence on the active site by that of a 209 
typical B2 enzyme (SfhI). We were able to express, purify, and characterize this construct. 210 
Despite that the change on SPM-1 represented as much as a 12.3 % modification of its primary 211 
structure, the enzyme tolerated the insertion, eliciting an active lactamase. This result confirms 212 
the proposed structural similarity between SPM-1 and B2 MBLs. The chimera retained the Zn(II) 213 
stoichiometry of B1 enzymes, showing that the insertion did not affect metal binding. 214 
It has been suggested that the sequence insertion might constraint the B2 MBLs substrate 215 
profile to render them exclusive carbapenemases. On the other hand, a role for the natural 216 
sequence insertion in SPM-1 has not been assigned, yet it could represent a hotspot for mutations 217 
that might change substrate-profile and catalytic parameters in a context-dependent way.  218 
The results obtained with SPM-1/Sfh-I indicate that the replacement of the native SPM-1 219 
sequence by that of a typical B2 enzyme, significantly affected ligand binding and turnover 220 
numbers by changing the substrate profile of the enzyme. The insertion sequence excluded 221 
certain substrates from the active site in a context-dependent way; unlike B2 enzymes (exclusive 222 
carbapenemases), in the surroundings of SPM-1 this segment favors the hydrolysis of 223 
cephalosporins over penicillins and carbapenems. Compared to wild type SPM-1, the hybrid 224 
MBL revealed a sharp decrease on kcat/KM values of 48 times for penicillin G and 34 times for 225 
piperacillin. These reductions in the catalytic efficiency values were associated to a major 226 
increase in KM and, less significantly to an increase in the turnover number. Thus, the presence 227 





















of the typical B2 sequence insertion restricted the access of penicillins to the active site, even 228 
within the context of a B1-subclass enzyme.   229 
In the case of imipenem, the loop change did not affect the antibiotic binding as reflected in 230 
KM values, but still presented a 17-fold decrease on kcat/KM attributable to an increase in the 231 
turnover. These results suggest that imipenem binding could be independent of residues in the 232 
native sequence insertion of SPM-1. Alternatively, KM values could indicate that the B2 233 
sequence insertion in the chimera might be locking imipenem in the active site after first 234 
contacts, but not penicillins substrates. If this was the case, then B2 sequence insertion in their 235 
native context might be playing a role at securing carbapenems but not other substrates to the 236 
catalytic site. However, in the scaffold of SPM-1 the correct position of imipenem for 237 
nucleophilic attack may not be achieved, thus yielding high turnover values.  238 
In clear contrast, cephalosporins kinetic parameters were barely affected by the presence or 239 
amino acid composition of the sequence insertion. The drop in kcat/KM values for cefotaxime 240 
increased 3-fold while it remained almost unaltered for ceftazidime. In the cases of cefuroxime 241 
and cephaloridine there was a minor drop in kcat/KM values of 3 and 5-fold, respectively.  242 
Analysis of the catalytic parameters for cefotaxime show that there was a 5-fold increase in 243 
its KM, while its turnover number was mostly affected by the loop modifications in SPM-1 244 
resulting in a 13-fold increase. Thus, contrasting what was proposed for imipenem, the sequence 245 
insertion of ShfI in the context of SPM-1 might help orienting the substrate for proper hydrolysis 246 
within the active site. All the changes observed in the kinetic parameters can be attributed to the 247 
B2-insertion and not to removal of the SPM-1 stretch, since previous studies have shown that 248 
elimination of the 24-aminoacid insertion in SPM-1 did not affect significantly the enzyme 249 
activity (14). 250 





















Despite the fact that the hybrid MBL showed in vitro activity against cephalosporins, it did 251 
not confer resistance in vivo. MICs reflect not only catalytic efficiencies, but also expression 252 
levels, folding behavior, and accessibility of the enzymes to the substrates within the bacterial 253 
periplasm. Considering that bacterial cultures were grown below the melting temperature for 254 
SPM-1/Sfh-I, one could argue that under these conditions the protein should be properly folded. 255 
However, if we consider that the unfolding transition begins at approximately 37 °C, and that in 256 
vivo there are molecular crowding effects accelerating protein aggregation, the results obtained 257 
would account for the loss of solubility in the periplasm. In fact, a role in protein stability has 258 
been recently assigned to the α3 insertion of CphA B2 enzyme (28), further supporting this 259 
hypothesis.   260 
The suboptimal context of the B2 insertion in the chimera unmasks different mechanisms of 261 
exclusion for each type of β-lactam antibiotics. In this way, sequence insertions in α3 may act as 262 
substrate-regulatory modules able to favor or exclude specific antibiotics in a context-dependent 263 
way. Incorporation of these modules may be an evolutionary strategy for drastic modification of 264 
substrate profiles in MBLs, followed by mutations in second-shell residues for further fine-265 
tuning. Overall, the results reveal that there are alternative evolutionary pathways still 266 
unexplored in nature that may benefit from the stable scaffold of MBLs to accumulate insertions, 267 
deletions and mutations giving rise to novel activities or resistance phenotypes.   268 
 269 
MATERIALS AND METHODS  270 
Bacterial Strains and Reagents 271 
E. coli DH5α was used for construction of plasmid pMBLe-blaSPM-1/Sfh-I. P. aeruginosa 272 
PAO1 and E. coli DH5α were used for expression of the pMBLe-blaSPM-1/Sfh-I and pMBLe-273 
blaSPM-1 constructs in resistance and cellular fractionation studies. E. coli BL21 (DE3) was used 274 





















for overexpression of recombinant proteins. Unless otherwise noted, all strains were grown 275 
aerobically at 37 °C in lysogeny broth (LB) medium supplemented with gentamicin 20 μg/mL or 276 
kanamycin 50 μg/ml when necessary. Chemical reagents were purchased from Sigma-Aldrich, 277 
molecular biology enzymes from Promega, and primers from Invitrogen. 278 
 279 
Plasmid Vectors 280 
The nucleotidic sequence of blaSPM-1/Sfh-I was synthesized by Genscript (USA) and PCR-281 
amplified with primers SPM-1NdeI-Fw (5′-282 
GTACGTCATATGAATTCACCTAAATCGAGAGC-3′) and SPM-1StHindIII-Rv (5′-283 
GTACGTAAGCTTCTACTTTTCGAATTGTGGGTGAGACCACAGTCTCATTTCGCCAAC-284 
3′) for subcloning into pMBLe-blaSPM-1 plasmid (7) through NdeI and HindIII sites. The resulting 285 
construct, pMBLe-blaSPM-1/Sfh-I, allows expression of SPM-1/Sfh-I with the native peptide leader 286 
of SPM-1, and fused to a Strep-Tag II sequence at the C-terminus (for comparative protein 287 
detection and quantification with respect to SPM-1). For protein overexpression, the regions 288 
coding for mature SPM-1 and SPM-1/Sfh-I were PCR-amplified from pMBLe plasmids with 289 
primers SPM-1NdeIFw (5′-AGTCAGTCCATATGTCGGATCATGTCGACTTGCC-3′) and 290 
SPM-1XhoI-Rv (5′-AGTCAGTCCTCGAGGGTTGGGGATGTGAGACTAC-3′), and subcloned 291 
into plasmid pET-28a through NdeI and XhoI sites(7). The resulting plasmids allow production 292 
of mature SPM-1 and SPM-1/Sfh-I proteins with an N-terminal thrombin-cleavable his-tag. All 293 
PCRs were carried out using Platinum Pfx DNA Polymerase (Invitrogen) with the following 294 
thermal cycle: 3 min at 95 °C, 30 cycles of 15 s at 95 °C, 30 s at 55 °C and 1 min at 68 °C, and 295 
10 min at 68 °C. Plasmids were introduced into E. coli strains or P. aeruginosa PAO1 as 296 
previously described (29). All constructs were verified by DNA sequencing (University of 297 
Maine). 298 






















Cellular Localization and Resistance Determination 300 
Extraction of periplasmic proteins was performed as previously described (30). Briefly, 301 
2–3 mL of mid-log P. aeruginosa PAO1 (or E. coli DH5α) pMBLe-bla cultures were induced 302 
with 20 µM IPTG for 2 hours, were pelleted and cells washed once with 20 mM Tris pH 8, 150 303 
mM NaCl. Cells were resuspended in 20 mM Tris pH 8, 0.1 mM EDTA, 20% w/v sucrose, 1 304 
mg/mL lysozyme (from chicken egg white, Sigma-Aldrich, protein ≥90%), 0.5 mM PMSF 305 
(resuspension volume was normalized according to the formula V = 100 μL × OD600 × Vc, 306 
where Vc is the starting volume of culture sample), incubated with gentle agitation at 4 °C for 30 307 
min and finally harvested, obtaining the periplasmic extract in the supernatant. The pellet, which 308 
consists of spheroplasts, was washed in 20 mM Tris pH 8, 0.1 mM EDTA, 20% w/v sucrose and 309 
resuspended in the same volume of this buffer. MBL protein levels were determined by SDS-310 
PAGE followed by western blot with Strep-Tag II monoclonal antibodies (at 1:1,000 dilution 311 
from 200 μg/mL solution) (Novagen, 71590-3) and immunoglobulin G-alkaline phosphatase 312 
conjugates (at 1:3,000 dilution) (Biorad, 170-6520) in PVDF membranes (GE). Western blots 313 
with antibodies detecting periplasmic maltose-binding protein (Rockland Immunochemicals, 314 
200-401-385) and cytoplasmic GroEL (provided by A. Viale, IBR/CONICET-UNR) were 315 
performed as loading controls for periplasmic extracts and spheroplasts, respectively.  316 
β-Lactam MIC determinations were performed in LB medium supplemented with 20 µM 317 
IPTG using the agar macrodilution method, according to CLSI guidelines (31). 318 
 319 
Purification of Wild Type SPM-1 and Chimeric SPM-1/Sfh-I Proteins   320 
An overnight culture (40 mL) of the E. coli BL21 (DE3) pET-28a-bla was diluted in 4 321 
liters of fresh LB-kanamycin and grown with shaking at 37°C until OD600 nm of 0.8. Protein 322 





















expression was induced by addition of IPTG at a final concentration of 1 mM for 4 hours at 37 323 
°C. Bacterial cells were harvested and lysed by sonication in 30 ml of denaturating buffer 324 
containing 100 mM Tris pH 8, 100 mM phosphate, 8 M urea, 2 mM β-mercaptoethanol at 4°C. 325 
Cell debris was removed by centrifugation (20,000 rpm for 1 hour at 4°C) and proteins purified 326 
by Ni-NTA affinity cromatography (GE Healthcare) in denaturing buffer at pH 8, for loading and 327 
washing, and denaturing buffer at pH 4.5 for elution. His-tagged proteins were refolded by flash 328 
dilution in 1 L of refolding buffer (50 mM HEPES pH 7.5, 200 mM NaCl, 2 mM β-329 
mercaptoethanol, 5 mM imidazole) supplemented with 5 mM imidazole and 100 µM ZnSO4, at 4 330 
°C under vigorous agitation. Refolded proteins were concentrated by Ni-NTA affinity 331 
chromatography and eluted with refolding buffer containing 500 mM imidazole. His tags were 332 
cleaved by treatment with 1 mg of thrombin every 30 mg of fusion protein during 16 hours at 4 333 
°C, and eliminated through Ni-NTA chromatography in refolding buffer supplemented with 5 334 
mM imidazole. Purified SPM-1 and SPM-1/Sfh-I were concentrated using 10 kDa MW cutoff 335 
Centricon devices (Millipore) and dialyzed against 50 mM HEPES pH 7.5, 200 mM NaCl for 336 
further experiments. Protein concentrations were determined from absorbance at 280 nm using a 337 








 for 338 
SPM-1/Sfh-I (calculated from aromatic residues using Expasy ProtParam, available at http:// 339 
web.expasy.org/protparam/). 340 
 341 
Biochemical Characterization of the Enzymes  342 
The metal content in the protein samples was determined under denaturing conditions 343 
using the colorimetric metal chelator 4-(2-pyridylazo) resorcinol (PAR) as described previously 344 
(32). Circular Dichroism spectroscopy was used to test the global folding state of proteins. CD 345 
spectrums were performed at the far-UV (195-250 nm) on a Jasco J-810 spectropolarimeter with 346 





















quartz cuvettes of 0.1 and enzyme concentrations of 10 µM in 20 mM phosphate pH 7.5 at 25 347 
°C. The metal content of SPM-1/SfhI was performed by reaction of 10 µM of the denatured 348 
protein with Ellman’s reagent (33) in a buffer containing Hepes 10 mM, NaCl 200 mM, 349 
guanidine chloride 4 M, EDTA 50 mM, pH 7.4.  Absorbance at 412 nm was measured and the 350 
value was extrapolated to a “free-thiols” calibration curve done with reduced glutathione 351 
(SIGMA). 352 
Protein melting curves were obtained from samples aliquoted in 96-well plates using a 353 
RealPlex quantitative PCR instrument (Eppendorf), with SYPRO Orange dye (Sigma-Aldrich) as 354 
the fluorescent probe (34). A uniform final concentration of 30 X (supplied as a 5000 X stock 355 
solution) was used in all experiments. The dye was excited at 465 nm and emission recorded at 356 
580 nm using the instrument’s filters. A heating ramp of 1°C/min from 20°C to 95°C was used, 357 
and one data point acquired for each degree increment. The reactions were performed in 20 μl 358 
volume containing HEPES 10 mM pH 7.5, NaCl 200 mM with or without 10 µg of protein. 359 
Lysozyme (10 µg) was used as positive control. All experiments were done in triplicate, from 360 
two independent protein preparations. Values of Tm were obtained from non-linear fit of the 361 
melting curves to a sigmoid equation.  362 
 363 
Steady State Kinetic Assays 364 
Kinetic parameters were determined spectrophotometrically using a Jasco V-670 365 
spectrophotometer following initial reaction rates at different substrate concentrations. To 366 
estimate the antibiotic hydrolysis the following differential molar extinction coefficients were 367 
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 and piperacillin, Δε235 nm = 370 

























. Reaction medium was 10 mM HEPES pH 7.5, 200 mM NaCl and 5 µM ZnSO4 371 
at 30 °C. The plots of the dependence of initial rates on substrate concentration were fitted to the 372 
Michaelis-Menten equation using SigmaPlot 12.0. Reported kinetic parameters correspond to the 373 
average of at least two determinations with independent protein samples. The kcat values were 374 
corrected by the Zn(II) content of the protein samples as previously described (35). Antibiotics 375 
were purchased from Sigma-Aldrich, with the exception of imipenem (USP Pharmacopeia). All 376 
of them had a purity >95%. 377 
 378 
Molecular Dynamics Simulations 379 
We performed 100 ns MD simulations using AMBER14 package (23) starting from the 380 
crystal structure of SPM-1 in the open and close moiety (PDB code 2FHX and 4BP0) (14, 24) 381 
and Sfh-I (PDB code 3SD9). As crystallization of SPM-1
open
 was achieved with a vacant Zn2 382 
site, the metal site structure of SPM-1 was reconstructed by aligning it to the geometry of the 383 
Zn2 site of the homologous enzyme B. cereus BcII (PDB code 1BC2) (36, 37) as in our previous 384 
work (7). The initial structure of the chimeric protein SPM-1/Sfh-I was built in-silico through 385 
homology modelling by Modeller (Version 9.18) (38). To build our model we used both 386 
structures of SPM-1 and Sfh-I as templates. We used the same protocol to perform MD 387 
simulations as in our previous work (7, 39). Briefly, the systems were immersed in a box of 388 
water molecules TIP3P (40) and were simulated using periodic boundary conditions and Ewald 389 
sums for treating long-range electrostatic interactions (41). The SHAKE algorithm was applied 390 
to all hydrogen-containing bonds (42). Parm99 and TIP3P force fields implemented in AMBER 391 
were used to describe the protein and water, respectively (23). The force field of the active site 392 
(Zn, 
-
OH, Asp, Cys and His) was taken from the literature (43). The temperature and pressure 393 
were controlled by the Berendsen thermostat and barostat respectively, as implemented in 394 





















AMBER (23). Cut-off values used for the van der Waals interactions were 10 Å. Each initial 395 
system was minimized using a multistep protocol, then heated from 0 to 300 K, and finally a 396 
short simulation at constant temperature of 300 K, under constant pressure of 1 bar, was 397 
performed to allow the systems to reach proper density. These equilibrated structures were the 398 
starting point for 100 ns of MD simulations at 300 K in the NVT ensemble. 399 
 400 
Brownian Dynamics Simulations 401 
We calculated the collision probability between the different enzymes and the substrate 402 
using Brownian Dynamics simulations (44). The BD simulations were executed through the 403 
BrownDye package (45). The electrostatic potentials of the enzymes and substrates were 404 
calculated using the Adaptive Poisson Boltzman Solver (APBS) package (46). Substrate was 405 
started at an arbitrary distance (~20 Å) from the Zn2 center. 2,000,000 BD trajectories were 406 
performed starting from different enzyme configurations, which were taken from equilibrium 407 
MD simulations. Association probabilities were computed using the fraction of the trajectories 408 
that "reacted", according to the chosen reaction criterion. Reaction criterion used was the Zn2...N 409 
(β-lactam ring) distance, in which a value of 8 Å was considered the end of the BD trajectory. 410 
The relative probability of association was calculated by dividing the successful trajectories of 411 
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 549 
FIGURE LEGENDS 550 
Figure 1. Design of SPM-1/Sfh-I. (A) Structural alignment of SPM-1 (black/red) and Sfh-I 551 
(grey/yellow) showing substitutions (1:L119T; 2:Y223N; 3:D226F) and swapping of sequence 552 
insertions to render SPM-1/Sfh-I. (B) Sequence swapping displayed on crystal structures of 553 
SPM-1 (PDB: 2FHX) and Sfh-I (PDB: 3SD9). (C) Representation of native interactions 554 
accomodating α3 insertion in Sfh-I. Zinc ions are depicted as purple spheres. 555 
 556 
Figure 2. Western-blot of spheroplasts and periplasmic fractions from P. aeruginosa PAO1 and 557 
E. coli DH5α, producers of SPM-1 or SPM-1/Sfh-I. Cells containing the empty vector (-) were 558 
used as control. Anti-Strep-tag antibody was used to assess SPM-1 or SPM-1/Sfh-I production, 559 
while GroEL and MBP are spheroplasts and periplasm markers respectively. 560 
 561 





















Figure 3. Folding and thermal stability of SPM-1 and SPM-1/Sfh-1. (A) Far UV CD spectrum of 562 
wild-type SPM-1 (solid line) and SPM-1/Sfh-I hybrid protein (broken line). (B) Thermal 563 
denaturation of SPM-1 (solid line) and SPM-1/Sfh-I (broken line) followed by thermal shift (Tm 564 
SPM-1/Sfh-I= 51 ± 1 °C, Tm SPM-1= 75 ± 0.5 °C). 565 
 566 
Figure 4. (A) Representative snapshots of the MD simulations of SPM-1
open







 (pink) and Sfh-I (dark yellow), showing the 568 
accessibility of the active site. (B) Relative probability of association of the enzymes with PenG.  569 
 570 
TABLES 571 
Table 1. MIC values for wild type SPM-1 and SPM-1/Sfh-I expressing bacterial strains. Both E. 572 
coli and P. aeruginosa were transformed with expression vectors for SPM-1 and SPM-1/Sfh-I 573 
enzymes and challenged to different β-lactam antibiotics. Cells containing the empty vector (-) 574 


























Table 2. β-Lactam hydrolysis parameters of SPM-1 and SPM-1/Sfh-1. β-Lactamase activities 580 
were measured at 30 °C in Hepes 10 mM, NaCl 200 mM, pH 7.5 supplemented with 5 µM 581 
Zn(II). Data come from three independent experiments, and are presented as mean ± s.d.  582 
 583 
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